((2S,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)methyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate | 134071-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((2S,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)methyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate
• 英文别名: cis-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethyl toluene-p-sulphonate；[(2S,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl 4-methylbenzenesulfonate
• CAS: 134071-44-6；85650-50-6
• 化学式: C₂₁H₂₀Cl₂N₂O₅S
• 分子量: 483.372
• InChiKey: WAXNIYHZFWRPGS-LAUBAEHRSA-N

物化性质

• 沸点：
  665.7±55.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  88
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  2,4-二氢-4-[[4-(4-羟基苯基)-1-哌嗪基]苯基]-2-(1-甲基丙基)-3H-1,2,4-三氮唑-3-酮 、 ((2S,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)methyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.0h， 生成 4-(4-(4-(4-(((2S,4R)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-(sec-butyl)-1H-1,2,4-triazol-5(4H)-one
  参考文献：
  名称：

  Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition

  摘要：

  Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 mu M). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.

  DOI：

  10.1021/acs.jmedchem.8b01252
• 作为产物：
  描述：

  2-溴-2',4'-二氯苯乙酮 在 三氟甲磺酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 76.0h， 生成 ((2S,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)methyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition

  摘要：

  Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 mu M). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.

  DOI：

  10.1021/acs.jmedchem.8b01252

文献信息

• Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors
  作者：Yingjun Li、Kalyan Kumar Pasunooti、Hanjing Peng、Ruo-Jing Li、Wei Q. Shi、Wukun Liu、Zhiqiang Cheng、Sarah A. Head、Jun O. Liu

  DOI：10.1021/acsmedchemlett.9b00438

  日期：2020.6.11

  group is replaced with pyridine or fluorine-substituted benzene was synthesized. Among them the pyridine- and tetrazole-containing compound 24 has significantly improved solubility and reduced CYP3A4 inhibition compared to itraconazole. Similar to itraconazole, compound 24 inhibited the AMPK/mTOR signaling axis and the glycosylation of VEGFR2. It also induced cholesterol accumulation in the endolysosome

  伊曲康唑是一种广泛使用的抗真菌药物，被发现具有抗血管生成活性，目前正接受多种临床试验来治疗不同类型的癌症。但是，它具有极低的溶解度和通过抑制CYP3A4与许多药物的强烈相互作用，限制了其作为新的抗血管生成和抗癌药物的潜力。为了解决这些问题，合成了一系列类似物，其中苯基被吡啶或氟取代的苯取代。其中，与伊曲康唑相比，含吡啶和四唑的化合物24的溶解度显着提高，并且对CYP3A4的抑制作用降低。与伊曲康唑相似，化合物24抑制AMPK / mTOR信号轴和VEGFR2的糖基化。在模拟研究中，它还诱导胆固醇在溶酶体中积累，并证明与NPC1的固醇感应域结合。这些结果表明，化合物24可以作为开发新一代抗血管生成药物的有吸引力的候选物。
• Sorbitol dehydrogenase inhibitors
  申请人：Chu-Moyer Y. Margaret

  公开号：US20050020578A1

  公开（公告）日：2005-01-27

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula 1, wherein R 1 , R 2 and R 3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of, treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

  本发明涉及式1的山梨醇脱氢酶抑制化合物，其中R1、R2和R3如规范中所定义。本发明还涉及包含这些化合物的制药组合物，并通过向患有糖尿病并因此有发展这些并发症风险的哺乳动物投与这些化合物来治疗或预防糖尿病并发症，尤其是糖尿病神经病变、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病。本发明还涉及包含本发明式I化合物与醛固酮还原酶抑制剂的组合物的制药组合物，并用于治疗或预防糖尿病并发症。本发明还涉及包含本发明式I化合物与NHE-1抑制剂的组合物的制药组合物，并用于治疗心肌病和其他心脏相关问题。本发明还涉及用于合成本发明式I化合物的某些中间体以及制备这些中间体的方法。
• Inhibition of hedgehog signaling by stereochemically defined des-triazole itraconazole analogues
  作者：Jiachen Wen、Kelly A. Teske、M. Kyle Hadden

  DOI：10.1016/j.bmcl.2019.126794

  日期：2020.1

  Dysregulation of the hedgehog (Hh) signaling pathway is associated with cancer occurrence and development in various malignancies. Previous structure-activity relationships (SAR) studies have provided potent Itraconazole (ITZ) analogues as Hh pathway antagonists. To further expand on our SAR for the ITZ scaffold, we synthesized and evaluated a series of compounds focused on replacing the triazole. Our results demonstrate that the triazole region is amenable to modification to a variety of different moieties; with a single methyl group representing the most favorable substituent. In addition, nonpolar substituents were more active than polar substituents. These SAR results provide valuable insight into the continued exploration of ITZ analogues as Hh pathway antagonists.
• US6946460B2
  申请人：——

  公开号：US6946460B2

  公开（公告）日：2005-09-20